This is an international, one day and a half workshop in which international experts will present the hot topics in the management of aging people. One European meeting in Barcelona and a second meeting in Buenos Aires during 2017, will be held.
Barcelona, 24-25th November 2016
Currently in high-income countries, 50% of HIV-infected subjects are over 50 years of age and the proportion of infected people older than 65 years grew 10-fold in the last years.
Aging is associated with the decline and deterioration of functional properties at the cellular, tissue and organ level that yields a loss of homeostasis and decreased adaptability to internal and external stress. All these changes increase the vulnerability to disease and mortality. Atherosclerosis and cardiovascular events, loss of renal function, osteopenia/osteoporosis, and non–AIDS-defining cancers are some of the emerging conditions observed in large observational cohorts of HIV-infected subjects whose incidence seems to be higher than in the general population. The increased life expectancy of this population together with the HIV-related chronic inflammation and the long exposure to some antiretroviral drugs are the main reasons of the accelerated aging in these patients.
Healthcare professionals agree that a special management of aging people reduces morbidities and mortality, as well as improves quality of life and conserves the ability to carry out the activities of daily living. In addition, an individualized and carefully choice of the antiretroviral combination should be considered in this population due to the polypharmacy and the drug-drug interactions, common in among these patients.
The objective of the workshop is to review the hottest topics on HIV infection and aging from a multidisciplinary point of view, as well as to provide an up to date overview of other issues such as the emergence of resistance mutations to the new antiretroviral drugs or the management of the HIV/HCV coinfection in the aging HIV-infected population.
This workshop is therefore aimed not only to healthcare professionals but also to researchers, representatives from educational institutions and academia, as well as, pharmaceutical industries.